

CORRECTION

Open Access



Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

Lorenzo Castagnoli¹, Alma Franceschini¹, Valeria Cancila², Matteo Dugo³, Martina Bigliardi¹, Claudia Chiodoni⁴, Paolo Toneguzzo¹, Viola Regondi¹, Paola A. Corsetto⁵, Filippo Pietrantonio⁶, Serena Mazzucchelli⁷, Fabio Corsi⁸, Antonino Belfiore⁹, Andrea Vingiani^{9,10}, Giancarlo Prunerì^{9,10}, Francesca Ligorio^{6,11}, Mario P. Colombo⁴, Elda Tagliabue¹, Claudio Tripodo^{2,11}, Claudio Vernieri^{6,11}, Tiziana Triulzi¹ and Serenella M. Pupa^{1*}

Correction: J Exp Clin Cancer Res 44, 19 (2025)
<https://doi.org/10.1186/s13046-025-03276-z>

The author group has been updated above and the original article [1] has been corrected.

Following the publication of the original article [1], the authors identified an errors in the author names of Antonino Belfiore and Andrea Vingiani. The correct names are presented below:

The incorrect author name is: Antonio Belfiore
The correct author name is: Antonino Belfiore

The incorrect author name is: Antonio Vingiani
The correct author name is: Andrea Vingiani

Published online: 30 May 2025

Reference

1. Castagnoli L, Franceschini A, Cancila V, et al. CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer. *J Exp Clin Cancer Res*. 2025;44:19. <https://doi.org/10.1186/s13046-025-03276-z>.

The original article can be found online at <https://doi.org/10.1186/s13046-025-03276-z>.

*Correspondence:

Serenella M. Pupa

Serenella.Pupa@istitutotumori.mi.it

¹ Microenvironment and Biomarkers of Solid Tumors Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

² Tumor Immunology Unit, Department PROMISE, Università Di Palermo, Palermo, Italy

³ Breast Cancer Unit Clinical Translational and Immunotherapy Research, Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy

⁴ Molecular Immunology Unit, Department of Experimental Oncology, Amadeolab Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

⁵ Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università Di Milano, Milan, Italy

⁶ Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

⁷ Department of Biomedical and Clinical Sciences, Università Di Milano, Milan, Italy

⁸ Surgery Department, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy

⁹ Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, Milan, Italy

¹⁰ Department of Oncology and Hemato-Oncology, Università Di Milano, Milan, Italy

¹¹ IFOM ETS, The AIRC Institute of Molecular Oncology, Milan, Italy



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.